AGL 38.80 Decreased By ▼ -0.78 (-1.97%)
AIRLINK 131.40 Increased By ▲ 0.18 (0.14%)
BOP 6.77 Decreased By ▼ -0.04 (-0.59%)
CNERGY 4.65 Decreased By ▼ -0.06 (-1.27%)
DCL 8.45 Increased By ▲ 0.01 (0.12%)
DFML 41.00 Decreased By ▼ -0.47 (-1.13%)
DGKC 81.76 Decreased By ▼ -0.33 (-0.4%)
FCCL 32.83 Decreased By ▼ -0.27 (-0.82%)
FFBL 72.39 Decreased By ▼ -0.48 (-0.66%)
FFL 12.51 Increased By ▲ 0.25 (2.04%)
HUBC 110.80 Increased By ▲ 0.06 (0.05%)
HUMNL 14.10 Decreased By ▼ -0.41 (-2.83%)
KEL 5.13 Decreased By ▼ -0.06 (-1.16%)
KOSM 7.65 Increased By ▲ 0.04 (0.53%)
MLCF 38.70 Decreased By ▼ -0.20 (-0.51%)
NBP 63.03 Decreased By ▼ -0.98 (-1.53%)
OGDC 189.85 Decreased By ▼ -2.97 (-1.54%)
PAEL 25.46 Decreased By ▼ -0.22 (-0.86%)
PIBTL 7.40 Increased By ▲ 0.06 (0.82%)
PPL 150.00 Decreased By ▼ -4.07 (-2.64%)
PRL 25.46 Decreased By ▼ -0.37 (-1.43%)
PTC 17.50 Decreased By ▼ -0.31 (-1.74%)
SEARL 81.26 Decreased By ▼ -1.04 (-1.26%)
TELE 7.72 Decreased By ▼ -0.04 (-0.52%)
TOMCL 33.00 Decreased By ▼ -0.46 (-1.37%)
TPLP 8.38 Decreased By ▼ -0.11 (-1.3%)
TREET 16.87 Increased By ▲ 0.25 (1.5%)
TRG 58.05 Increased By ▲ 0.65 (1.13%)
UNITY 28.10 Increased By ▲ 0.59 (2.14%)
WTL 1.35 Decreased By ▼ -0.02 (-1.46%)
BR100 10,465 Decreased By -39 (-0.37%)
BR30 30,935 Decreased By -291 (-0.93%)
KSE100 97,705 Decreased By -374.4 (-0.38%)
KSE30 30,408 Decreased By -150.6 (-0.49%)

Health-care products maker Johnson & Johnson won US approval to sell a new HIV drug called Intelence for patients with resistance to other therapies, US officials said on Friday. The drug, also known as TMC125 or etravirine, is a new member of the family of AIDS-fighting drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI).
More than two dozen drugs are approved for fighting the deadly HIV virus. Patients need new options because HIV can mutate to resist existing treatments.

Copyright Reuters, 2008

Comments

Comments are closed.